Which top 10 big pharmas have the most to gain — or lose — over the next 5 years?
When Evaluate Pharma crunched the likely drug sales numbers for the big 10, 2 stood out.
Takeda, with its big Shire buyout under its belt, is set to almost double its worldwide sales record for 2018 over 5 years, putting it in the big 10 — the 9th spot, to be exact — which is exactly where CEO Christophe Weber wants to be.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.